Overview

Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation

Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the efficacy and safety of administration of lubiprostone in patients with irritable bowel syndrome with constipation.
Phase:
Phase 3
Details
Lead Sponsor:
Sucampo Pharma Americas, LLC
Sucampo Pharmaceuticals, Inc.
Collaborators:
Sucampo Pharmaceuticals, Inc.
Takeda
Treatments:
Lubiprostone